Drugs / hUCMSC-Exos
hUCMSC-Exos
Trials 4
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1/23 trials | ||||||
| Phase 1/2 | NCT07519031 | Apr 2026 → Nov 2027 expected | vitiligo | Xijing Hospital | Not yet recruiting | No outcome recorded |
| Phase 1/2 | NCT07599111 | Apr 2026 → Jun 2028 expected | interstitial lung disease | Zhou Chengzhi | Not yet recruiting | No outcome recorded |
| Phase 1/2 | NCT07243561 | Sep 2025 → Oct 2026 expected | autism spectrum disorder | Dongfang People's Hospital | Recruiting | No outcome recorded |
| Phase not applicable1 trial | ||||||
| — | NCT07373054 | Nov 2025 → Jul 2026 | androgenetic alopecia | Fujian Medical University Union Hospital | Completed | No outcome recorded |
Evidence & citations 5 cited values
Every value below carries the sentence it was read from. 4 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | hUCMSC-Exos | “human umbilical cord mesenchymal stem cell-derived exosomes (hUCMSC-Exos) have emerged as a cell-free therapeutic strategy” NCT07373054 ↗ |
| Known as | human umbilical cord mesenchymal stem cell-derived exosomes | “human umbilical cord mesenchymal stem cell-derived exosomes (hUCMSC-Exos) have emerged as a cell-free therapeutic strategy” NCT07373054 ↗1“Human Umbilical Cord Mesenchymal Stem Cell-Derived Exosomes (hUC-MSC-Exos) Intravenous Infusion” NCT07519031 ↗ |
| Known as | hUMSCs-Exo | “This study evaluates whether exosomes derived from human umbilical cord mesenchymal stem cells (hUMSCs-Exo) are safe and effective for treating vitiligo in adults.” NCT07519031 ↗ |
| Modality | Other / unclassified | “exosomes derived from human umbilical cord mesenchymal stem cells (hUC-MSC-EXOs)” NCT07243561 ↗ |
| Route | Intranasal | “The treatment group will receive the nasal spray every other day” NCT07243561 ↗ |